The US Food and Drug Administration (FDA) denied approval for 3,4- methylenedioxymethamphetamine (MDMA) assisted therapy, and the academic and medical journal Psychopharmacology retracted three papers related to the trial. The FDA denial and Psychopharmacology’s response to ethical concerns cited drug trial participant selection, study design, and data manipulation. For future consideration, the FDA required an additional Phase III trial by Lykos Therapeutics. Background ...

A new schizophrenia drug revives the previously investigated drug xanomeline. Historically, physicians used xanomeline to treat Alzheimer’s disease until its removal from the market in 1998 because of gastrointestinal side effects. The investigation into its use for schizophrenia ceased for the same reason. However, an experimental drug, KarXT, combines xanomeline and trospium and takes a novel ...

Naltrexone shortages impact the United States according to social media users unable to fill their prescriptions. As of one month ago users on Reddit and other social media platforms, such as X (formerly Twitter), report being unable to fill their naltrexone prescriptions. Some individuals cite supply chain issues as their primary concern. As of March ...